Immix Biopharma Announces Dr. Suzanne Lentzsch, Director of the Multiple Myeloma and Amyloidosis Program at the College of Physicians and Surgeons of Columbia University and at New York Presbyterian Hospital in New York, Joins Scientific Advisory Board

• Dr. Lentzsch joins the Nexcella Scientific Advisory Board with decades of experience treating patients with AL Amyloidosis and multiple myeloma and serving as a principal investigator on clinical trials for novel agents.
• Dr. Lentzsch is an internationally recognized expert in multiple myeloma and AL Amyloidosis; Co-Chairs the National Cancer Institute Myeloma Steering Committee; is an Associate Editor of Journal of Clinical Oncology; was a key clinical investigator in establishing bendamustine as a new treatment for relapsed amyloidosis, the principal investigator of the CAEL-101 phase 1a/b study in AL Amyloidosis and co-founder of Caelum Biosciences, subsequently acquired by AstraZeneca.

LOS ANGELES, Sept. 01, 2023 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (“ImmixBio”, “Company”, “We” or “Us”), a clinical-stage biopharmaceutical company pioneering personalized therapies for oncology and immunology, announced that effective today, Dr. Suzanne Lentzsch has joined the Nexcella Scientific Advisory Board. Dr. Lentzsch brings extensive experience focused on new therapeutic agents across AL Amyloidosis and multiple myeloma to Nexcella. Dr. Lentzsch Co-Chairs the National Cancer Institute Myeloma Steering Committee; is an Associate Editor of Journal of Clinical Oncology; was a key clinical investigator in establishing bendamustine as a new treatment for relapsed amyloidosis, the principal investigator of the CAEL-101 phase 1a/b study in AL Amyloidosis and co-founder of Caelum Biosciences, subsequently acquired by AstraZeneca.

“I have been fortunate to lead efforts to conduct clinical trials resulting in new treatment options for patients with relapsed/refractory AL amyloidosis and relapsed/refractory multiple myeloma,” said Dr. Lentzsch. “Nexcella is developing an autologous CAR-T with clinical results that are encouraging in relapsed AL Amyloidosis and relapsed multiple myeloma. I am thrilled to join the Nexcella Scientific Advisory Board.”

"We are delighted to be joined by Dr. Lentzsch on the Nexcella Scientific Advisory Board," stated Ilya Rachman, MD PhD Chief Executive Officer of Immix Biopharma. Gabriel Morris, Chief Financial Officer of Immix Biopharma, added: “Dr. Lentzsch’s wealth of experience as a principal investigator in clinical trials for AL amyloidosis and myeloma bringing new treatment options to patients is uniquely moving. We are looking forward to collaborating with Dr. Lentzsch.”